Ataxia Investigators Meeting 2016: From Basic Science to Clinical Therapeutics

2016 年共济失调研究者会议：从基础科学到临床治疗

基本信息

批准号：
9051026
负责人：
DAVID ROBINSON LYNCH
金额：
$ 3.5万
依托单位：
CHILDREN'S HOSP OF PHILADELPHIA
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-30 至 2016-09-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9051026
关键词：
Address Affect Ataxia Basic Science Biological Cerebellar degeneration Clinical Clinical Trials Collaborations Communication Country Deglutition Disease Economics Elements Ensure Etiology Europe Eye Movements Family Florida Foundations Funding Future Gait Genetic Genomics Goals Human Industry International Location Movement Multi-Institutional Clinical Trial Nature Patients Phase Postdoctoral Fellow Prevalence Recruitment Activity Research Research Personnel Route Scientific Advances and Accomplishments Scientist Speech Therapeutic Therapeutic Human Experimentation Time Translational Research United States United States National Institutes of Health abstracting base dexterity genetic approach graduate student lectures meetings motor control nervous system disorder novel therapeutic intervention posters programs public health relevance success symposium therapeutic target translational approach

项目摘要

DESCRIPTION (provided by applicant): Ataxia, a disabling and frequently fatal neurological disorder, results from a wide variety of genetic and acquired etiologies. The 6th Ataxia Investigators' Meeting, "AIM 2016: From Basic Science to Clinical Therapeutics" will assemble an international roster of investigators to address the diverse causes of ataxia, to define better the pathogenic basis of ataxia, and to explore routes to therapy. The conference will focus on the most recent scientific advances and emerging integrative approaches toward therapy, with the following objectives: 1) Identify common disease mechanisms, 2) Explore therapeutic strategies, 3) Help establish the future leaders of ataxia research, and 4) Bring trainees (graduate students and postdocs) into contact with ataxia patients and families. AIM 2016 will represent a critical mechanism to facilitate collaboration and discussion on ataxia research and therapeutic approaches, which is of particularly great importance now that the field is entering the phase of meaningful, multi-center clinical trials both in the United States and Europe. The AIM 2016 meeting, affiliated and overlapping with the annual meeting of the largest ataxia foundation in the country occurring at the same hotel, will maximize the impact of this meeting for scientists and patients alike.

描述（应用程序提供）：共济失调是一种残疾且经常致命的神经系统疾病，是由多种遗传和获得的病因引起的。第六个共济失调研究者的会议“ AIM 2016：从基础科学到临床治疗学”将组建一个国际研究人员阵容，以解决共济失调的潜水员原因，以更好地定义共济失调的致病基础，并探索治疗途径。该会议将重点关注最新的科学进步和新兴的治疗方法，并具有以下对象：1）确定常见的疾病机制，2）探索理论策略，3）帮助建立共济失调研究的未来领导者，以及4）将受训者（研究生和博士后）带入与共生患者和家庭的接触。 AIM 2016将代表一种关键机制，以促进有关共济失调研究和理论方法的协作和讨论，这一点非常重要，因为该领域正在进入美国和欧洲的有意义的，多中心的临床试验阶段。 AIM 2016会议，会员和与同一酒店中最大的共济失调基金会年度会议重叠，这将最大化这次会议对科学家和患者的影响。